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The leading probiotics currently available to consumers are generally drawn from a narrow range of 15 
organisms. Knowledge of the gut microbiota and its constituent actors is changing this paradigm, 16 
particularly given the phylogenetic range and relatively unknown characteristics of the organisms 17 
under investigation as novel therapeutics. For this reason, and because their development is likely to 18 
be more amenable to a pharmaceutical than a food delivery route, these organisms are often 19 
operationally referred to as Next Generation Probiotics, a concept which overlaps with the newly 20 
emerging concept of Live Biotherapeutic Products. The latter is a class of organisms developed 21 
exclusively for pharmaceutical application. In this perspective we discuss what lessons have been 22 
learned from working with traditional probiotics, explore the kinds of organisms likely to be used as 23 
novel microbial therapeutics, discuss the regulatory framework required, and propose how scientists 24 





Pro ioti s are defi ed as live microorganisms that, when administered in adequate amounts, confer 28 
a health benefit on the host 1. Probiotics have a centuries-long history of safe use (Fig. 1) but have 29 
only been recognised as being of economic value during the 20th century. The global probiotics market 30 
is projected to reach a turn-over value of USD$46.55 billion by 2020 31 
(http://www.marketsandmarkets.com/PressReleases/probiotics.asp), and is dominated by food 32 
companies, nutritional supplement companies, and dedicated probiotic production companies. The 33 
probiotic organisms that feature in these products have been mainly sourced from the gut or from 34 
traditional fermented foods such as pickles, yoghurts, and kefir grains.  Thus the majority of the 35 
probiotics sold and used both in probiotic research and commercial probiotic development are from 36 
a limited list of genera, which mainly include Lactobacillus spp. and Bifidobacterium spp.  The more 37 
commonly exploited strains/species among the lactobacilli and bifidobacteria have been accepted as 38 
having Generally Regarded as Safe (GRAS) status in the United States 39 
(http://www.accessdata.fda.gov/scripts/fdcc/?set=GRASNotices) or have been granted Qualified 40 
Presumption of Safety status by the European Food Safety Authority (EFSA)2. Other probiotics 41 
currently available in the marketplace include Saccharomyces, Bacillus spp., Escherichia coli, 42 
enterococci and Weissella spp. We consider it likely that these organisms will continue to be 43 
developed and regulated under the current mechanisms for probiotics rather than the novel pathways 44 
discussed below. 45 
With the development of better culturing methodologies, more affordable genome and 46 
metagenome sequencing and more powerful tools to edit and modify bacterial genomes, we are now 47 
on the cusp of a new era in probiotic research, one which allows us to develop bespoke probiotics that 48 
address specific consumer needs and issues.  The knowledge of the composition and function of the 49 
human gut microbiome, also accelerated by massively parallel sequencing, has dramatically extended 50 
the range of organisms with potential health benefits, although many of these are still at the very early 51 
stage of mechanistic investigation (Table 1). These organisms are sometimes referred to as Next 52 
Generation Pro ioti s  but may also be termed Live Biotherapeutic Products  LBPs3) in the context 53 
of a new regulatory framework in the USA (see below).  Both academic and industry scientists are 54 
faced by a set of challenges which partly mirror those faced in recent decades by those engaged in 55 
probiotic research, but which have additional distinguishing issues that may facilitate or complicate 56 
their commercial development. There are many other candidate therapeutic organisms in various 57 
phases of development in the burgeoning microbiome-based biopharma sector but Table 1 entries 58 
are restricted to selected examples that have been published, and preferably tested in humans. 59 
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Expanding this parsimonious list will require completion of pre-clinical safety trials, and safety and 60 
efficacy trials in humans. 61 
 62 
What is a Next Generation Probiotic? 63 
Next Generation Probiotics (NGPs) obviously conform to the normal definition of a probiotic, but in 64 
this discussion we are primarily referring to those microbes which have not been used to date as 65 
agents to promote health, and which are more likely to be delivered under a drug regulatory 66 
framework (Fig. 2). NGPs also fit well within the US Food and Drug Administration definition of Live 67 
Biotherapeutic Produ t: a iologi al produ t that:  o tai s li e orga is s, su h as a teria;  is 68 
applicable to the prevention, treatment, or cure of a disease or condition of human beings; and 3) is 69 
ot a a i e.  70 
(http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformatio71 
n/Guidances/General/UCM292704.pdf). 72 
Given that the term LBP is now a formally recognised concept, at least in the USA, one may reasonably 73 
question if a term such as NGP is necessary at all. We suggest that at this juncture that classifying 74 
certain microbes as NGPs can serve a useful purpose, in that the term emphasises that they differ 75 
from traditional probiotics in how they are likely to be viewed by regulators, and recognises the 76 
likelihood that NGPs will also include genetically modified microorganisms (GMMs). Probiotics have 77 
been largely included in food delivery vehicles or as supplements, marketed and regulated as foods or 78 
functional foods, and are clearly positioned in consumer perception a long way from the controversial 79 
issue of GMMs or Genetically Modified Food. Since the likely route to market for LBPs and NGPs will 80 
follow a path marked by studies of preclinical mode of action, safety, pharmacokinetics, 81 
pharmacodynamics, phase 1-3 trials, accompanied by passing appropriately timed regulatory approval 82 
hurdles (see below), it seems that referring to these organisms as simpl  pro ioti s  ill ge erate 83 
confusion rather than clarity, to scientists and consumers alike. 84 
It is also worth considering if both terms NGP and LPB are different and necessary. The differences are 85 
mainly but not exclusively operational ones; NGPs tend to be investigated by laboratories previously 86 
engaged in probiotic and microbiome research and often have a development trajectory based on the 87 
probiotic experience in the laboratory; LBPs tend to be investigated by start-up biotechnology 88 
companies or pharmaceutical companies with the expressed intention of seeking approval for 89 
pharmaceutical marketing. GM probiotics arguably span both label domains, with there being a 90 
reasonable case that calling them LBPs rather than NGPs is less likely to erode consumer confidence 91 
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that probiotics are simple unmodified organisms. We suggest that NGP is a reasonable attempt to 92 
mark the transition from traditional microbes with long histories of safe use, to untried microbes with 93 
no such historical acceptance. In time, we believe that the term NGP will disappear and its members 94 
will either merge with current probiotics or will take a pharmaceutical route to market, in which case 95 
they would be developed as LBPs. 96 
Examples of current NGP candidates 97 
A scan of the primary literature for the period of 2000- 6 usi g the ter  pro ioti *  reveals 16,064 98 
articles, 9,811 of which contain the word Lactobacillus and 3,463 Bifidobacterium, either in the title 99 
or abstract.  The majority of papers that mentioned non-canonical probiotic genera, for example 100 
Clostridium or Bacteroides, did so in the context of these genera being pathogenic strains to be 101 
modulated by the consumption of the probiotic, rather than as actual probiotics.  Furthermore, any 102 
conflations of the term with other genera such as Faecalibacterium or Akkermansia were very rare.  103 
Where non lactobacilli or bifidobacterial probiotics were mentioned, it is evident that there are two 104 
strategies being employed to develop them as NGPs. As with current probiotics, one strategy involves 105 
associating the presence or absence of a specific strain with a health phenotype and exploring whether 106 
the chosen strain, when administered in sufficient quantities, can recapitulate the health phenotype.  107 
The second strategy is to adopt a well-characterised probiotic strain and use them as delivery vehicles 108 
for a specific molecule, again choosing the molecule to be delivered based on either a strong 109 
association or some mechanistic insight which shows that addition of the molecule would abrogate 110 
the disease phenotype and thus promote health. 111 
The two most abundant families in the colon are Bacteroidales and Clostridiales. The former are being 112 
explored as potentially novel second-generation probiotics. For example, Deng and colleagues 4 113 
isolated B. fragilis strain ZY-312 from the faeces of a healthy breastfed infant and proceeded to show 114 
that the organism possessed potentially health promoting phenotypes when incubated with 115 
colonocytes and macrophages.  These phenotypes include the promotion of the production of 116 
microbicidal molecules and phagocytic functions in macrophages. However, these functions appear 117 
to be strain dependent; for example B. fragilis has been reported to make fragilysin 5,6 which has been 118 
implicated as a risk factor for developing colorectal cancer 7, which would not be a desirable trait in a 119 
next-generation probiotic.  The bacterial polysaccharide, PSA, which was reported in 2005 8 is another 120 
probiotic feature of B. fragilis.  PSA is part of a larger family of zwitterionic polysaccharides (ZPS) and 121 
has been reported to play an immunomodulatory role, and depending on the type of polysaccharide, 122 
this can be either immunoregulatory or pro-inflammatory.  These results show that it is important to 123 
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identify the strain being used because its health promoting features will be closely aligned to its 124 
evolutionary history, a feature which is also true for traditional probiotics. 125 
Bacteroides xylanisolvens DSM 23964 has also been considered an NGP. It was isolated from human 126 
faeces, and does not encode the Bacteroides fragilis enterotoxin or produce PSA 9.  It has been shown 127 
to be tolerated in Phase I trials 9, and in a later study in humans the same team showed that the heat 128 
inactivated preparation of this organism was able to increase the levels of Thomsen-Friedenreich (TFα) 129 
specific IgM antibodies in a manner which was dose-dependent and time constrained 10. The authors 130 
speculated that an increase in these antibodies would promote a more robust response to cancer and 131 
thus a eliorate the host s o  a er i u e sur eilla e s ste  10. However, by heat inactivating 132 
the organism they are effectively contravening what is one of the defining characteristics of probiotics; 133 
that it must be a living organism. Furthermore, the desired outcome, to prevent cancer, is a difficult 134 
one to prove, as it will require large cohorts prospectively studied over 20-30 years to assess efficacy. 135 
Other Bacteroides spp. have also been considered as potential NGPs; Bacteroides dorei D8, has been 136 
shown to convert cholesterol to coprostanol in vitro, and may be considered as a probiotic in the 137 
context of the cholesterol-CVD axis; B. acidifaciens has been shown to increase IgA in gnotobiotic mice 138 
mono-associated with the bacterium 11and a strain of B. ovatus, when fed to mice, increased levels of 139 
anti-TFα IgM a d IgG a ti odies. 140 
The other common genus found in the colon, Clostridium, has not yet been explored to the same 141 
extent as the Bacteroides species complex. One strain, Clostridium butyricum MIYAIRI 588 (CBM 588; 142 
also referred to as C. butyricum FERM BP-2789), has been studied for over 50 years, mainly in Asia. 143 
From the limited number of publications it appears that this organism has been used to treat 144 
Clostridium difficile infections 12, Helicobacter pylori infections 13, cholesterol levels 14,15 and cancer 16. 145 
One of the most abundant species to be found in the large intestine is Faecalibacterium prausnitzii, 146 
which has been reported to be depleted in individuals with inflammatory bowel disease 17. Therefore, 147 
it seems reasonable that if there was a causal link between disease status and the absence of this 148 
organism, then by simply feeding it to the individual its health promoting features should be restored 149 
and thus it may be considered an NGP.  However, there is no evidence, either published or deposited 150 
at ClinicalTrials.gov, for this orga is s effi a  as a pro ioti  to e a le to re erse the s pto s of 151 
IBD when fed to humans. In animal models, evidence is available and feeding animals with F. 152 
prausnitzii does lead to or associate with induction of anti-inflammatory cytokines 18or reduction of 153 
pro-inflammatory cytokines 19in induced models of colitis/IBD. 154 
An alternative route to developing some NGPs is to take GRAS organisms or commensals and use them 155 
as a deli er  ehi le for a ioa ti e ole ule.  I  this approa h the a terial vehicle  is k o  ot to 156 
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produce any virulence factors and will be tolerated by the host and if chosen carefully, may not even 157 
colonise the host.  Two groups have used Lactococcus lactis strains (not normally considered to be 158 
probiotics) as their vehicle for delivering a range of anti-inflammatory molecules.  L. lactis was 159 
engineered to deliver the serine protease inhibitor, elafin, and shown that in an animal model of colitis 160 
administration of the GMO reduced elastolytic activity and inflammation 20.  Another laboratory 161 
engineered L. lactis to deliver several different human molecules, most notably IL-10 21 for controlling 162 
allergen sensitivity and Trefoil Factor 1 22 to treat oral mucositis, with other examples being covered 163 
in more detail elsewhere 23.  While these approaches used a GRAS food-derived bacterium as their 164 
delivery vehicle, the common colonic bacterium Bacteroides ovatus has been employed as a host to 165 
express and produce either murine IL-2 24, keratinocyte growth factor-2 (KGF-2) 25 or TGF-β  26, all 166 
under the control of a xylan inducible promoter, which was re-purposed from its original task of driving 167 
expression of the B. ovatus xylanase gene 27.  In one animal trial, TGF-β -producing B. ovatus was 168 
administered to mice with DSS-colitis, and induced production of the TGF-β  in situ, by inclusion of 169 
xylan in the drinking water. The authors concluded that this GMO was able to significantly improve 170 
the clinical scores and accelerate healing, and stated that the results are o para le a d ost ases 171 
superior to that a hie ed  o e tio al steroid therap  27. 172 
 173 
  174 
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Table 1. Selected examples of Next Generation Probiotics  175 
  176 
 177 
Organism Type Disease Target Level of Evidence Study type Ref 
Bacteroides xylanisolvens 
DSM 23694 
Natural (human) Cancer Medium: safety in humans 
has been established, 
hile le els of TFα spe ifi -
IgM have been shown to 
be elevated in humans. 
In human 10 
B. ovatus D-6 Natural (human) Cancer Low to medium: increases 
le els of uri e TFα 
specific-IgM and IgG. 
Pre clinical in mice 28 
B. ovatus V975 GMO (originally from 




Intestinal Inflammation Medium: Shows 
abrogation of symptoms of 
DSS induced in murine 
colitis model. 
Pre clinical in mice 25 
B. ovatus V975 GMO expressing Human 
transforming growth 
factor-β  TGF-β  
Intestinal inflammation Medium: Shows 
abrogation of symptoms of 
DSS induced in murine 
colitis model. 
Pre clinical in mice 26 
B. dorei D8 Natural (human) Heart disease Low, depletion of 
cholesterol in vitro 
Pre clinical in vitro 29 
B. fragilis ZY-312 Natural (human) Clearance of infectious 
agents 
Low: data only in vitro. Pre clinical in vitro 4 
B. acidifaciens JCM 10556(T) Natural (mouse) Clearance of infectious 
agents 
Low-medium: Increases 
IgA levels in the large 
intestine of gnotobiotic 
mice. 
Pre clinical in mice 11 
Clostridium butyricum 
MIYAIRI 588 
Natural (human) Multiple targets including 
cancer, inflammation and 
infectious agents 
Low-Medium: Evidence 
gathered for claims in 
human and animals trials 
In human 12-16,30-42 
 
 
Faecalibacterium prausnitzii Natural (human) Mainly IBD, but also 
asthma, eczema and Type II 
diabetes 
Low to Medium: Mainly 
focused animal models of 
colitis and in associative 
studies 
Pre clinical in mice and 
in vitro 
18,43,44 
L. lactis::elafin GMO (Host isolated from 
food) 
Mainly inflammatory 
disease such as IBD 
Medium: Good evidence 
from animal models of IBD 
Pre clinical in mice 20 
L. lactis:: Trefoil Factor 1 or 
IL-10 
GMO (Host isolated from 
food) 
Allergen sensitivity and 
autoimmune diseases – 
Type I Diabetes 
Medium: Mainly animal 
based efficacy. 
In humans Phase I trial 23 
 178 
 179 
  180 
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Issues facing the development and marketing of NGPs and LBPs 181 
 182 
Current EFSA and FDA positions on probiotics and LBPs 183 
The existing regulatory positions for probiotics are not consistent across all jurisdictions, and so we 184 
will briefly summarise the current situation in the United States and the European Union.  When 185 
considering regulatory positions on probiotics, it is important to recognize that probiotics can be 186 
utilized in a variety of different product types. Probiotics can be delivered in the form of conventional 187 
foods, infant formula, pet foods, dietary supplements, drugs, cosmetics and even medical devices1. 188 
The regulatory requirements and types of allowable claims for each of these products differ. Most 189 
probiotics today are components of either foods or dietary supplements.  190 
In the European Union the responsible regulatory agency is the European Food Safety Authority 191 
(EFSA).  The EFSA Panel on Dietetic Products, Nutrition and Allergies has evaluated over 400 probiotic 192 
applications, but has not reached a positive opinion on any health claims.  Indeed, even the use of the 193 
ter  pro ioti  has been effectively outlawed by an amendment which regulates the use of ge eri  194 
des riptors 45.  It is not clear whether any NGPs would be subjected to any additional regulatory 195 
scrutiny, but any genetically modified microbes would also have to be approved by the EFSA Panel on 196 
Genetically Modified Organisms, while the authorisation of any microbe as a drug would have to be 197 
authorised by the European Medicines Agency. 198 
I  the U ited “tates, regulator  authorities do ot use the ter  pro ioti . Even though precisely 199 
defined1, they instead use the term live microbial ingredients, when referring to ingredients in foods 200 
or dietary supplements, or live biotherapeutic agents when referring to use as a drug. With regard to 201 
claims in the United States, claims that a product can diagnose, cure, mitigate, treat, or prevent 202 
disease are only allowed on drugs.  Health benefit claims for foods or dietary supplements are of two 203 
types. The first type, an approved Health Claim, has not been used for probiotics. This claim relates to 204 
the ability of the food or supplement to reduce the risk of disease. This claim must be approved by 205 
the FDA or an authoritative body (such as the Institute of Medicine). The second type of claim is the 206 
structure/function claim. Such claims relate the probiotic to the normal structure and function of the 207 
healthy human body.  Recently, in the context of infant formula, the FDA expressed the opinion in a 208 
draft guidance that such claims are acceptable on dietary supplements, but that such claims on foods 209 
must relate to the taste, aroma or nutritive function of the food46. 210 
Importantly to the context of development of NGPs, the FDA positio  o  hat o stitutes a e  211 
dietar  i gredie t  ust e o sidered. I  August 6, the FDA pu lished a draft guida e o  this 212 
10 
 
topic47. This draft o tai s the state e t: Bacteria that have never been consumed as food are 213 
unlikely to be dietary ingredients.  I  short, a  pro ioti s o  the arket prior to the adoptio  of the 214 
dietary supplement regulations (Dietary Supplement Health and Education Act of 1994) in October 15, 215 
1994 can be grandfathered in as a dietary supplement ingredient. However, the FDA does not provide 216 
a direct path to a dietary supplement for any novel probiotics. If an NGP is first marketed in food, it is 217 
considered a dietary ingredient, and then has a path to become a dietary supplement. This is a 218 
cumbersome, indirect pathway that will likely result in any microorganisms being developed instead 219 
as LBPs. 220 
As stated earlier, the FDA Center for Biologic Evaluation and Research (CBER) defined a live 221 
iotherapeuti  produ t LBP  as a biological product that: 1) contains live organisms, such as bacteria; 222 
2) is applicable to the prevention, treatment, or cure of a disease or condition of human beings; and 3) 223 
is not a vaccine 48.  This would appear to be a very useful category which could be exploited for novel 224 
i ro es i ed  fro  the i ro iota.  CBER requires a very detailed characterisation of any 225 
microorganisms in this category, similar to that required for vaccines.  LBPs would have to be produced 226 
to Good Manufacturing Practice (GMP) standards.  CBER also allows for the development of 227 
recombinant LBPs, composed of microorganisms that have been genetically modified through the 228 
purposeful addition, deletion, or modification of genetic material.  The path for conducting human 229 
research on LBPs is clear, though we know of no examples that have completed it yet. The 230 
Investigational New Drug (IND) process must be followed. Over past years, the FDA had considered 231 
essentially all probiotic research to be drug research. Under the auspices of the International Scientific 232 
Association for Probiotics and Prebiotics (ISAPP), several researchers challenged FDA on this position, 233 
demonstrating the negative impact it has had on the conduct of human research on probiotics in the 234 
United States as well as pointing out that such research on foods or dietary supplements is legal under 235 
U.S. law49. Recently, the FDA relaxed their position, seemingly to provide a path for human research 236 
on probiotic foods or dietary supplements without needing an Investigational New Drug (IND) 237 
approval50. 238 
While EFSA is the competent authority for legislating and oversight with regard to probiotics, 239 
The European Directorate for the Quality of Medicines (EDQM) enables the development, 240 
implementation and monitoring of the application of quality standards for safe medicines and their 241 
use (https://www.edqm.eu/en/EDQM-mission-values-604.html). The EDQM appointed a Live 242 
Biotherapeutic Products Working Party in 2014, to develop a monograph for Live Biotherapeutic 243 
Products (LBPs). The purpose of this monograph will be to harmonise quality standards for LBPs as 244 




What do proponents of LBPs need to demonstrate? 247 
According to FDA regulations all LBP appli atio s ust i lude a des riptio  of the drug su sta e , 248 
to include the biological name and strain designations; the original source of cells from which the drug 249 
substance was derived; the culture/passage history of the strains; a description of the clinical health 250 
of the donor; a summary of the phenotype and genotype of the product strains; and documentation 251 
and summary of modifications, if any, to the LBP, e.g., intentional introduction of foreign genes or 252 
mutations, along with details of the genetic construction.  These demands should be possible for most 253 
LBPs isolated from the microbiome, although providing a complete description of the precise 254 
culture/passage history of the strains may be challenging for strains isolated a number of years ago. 255 
Co plete hara terisatio  of a  LBP ust also e pro ided.  This o prehe si e list i ludes, inter 256 
alia, methods for detection and identification, antibiotic resistance, methods used and a justification 257 
for any genetic manipulation, and any support for a mechanism of action.  The manufacturer must 258 
also provide a complete and comprehensive description of the manufacturing method and 259 
infrastructure, the materials used in the manufacturing process, and details of any other products 260 
produced in the same facility. 261 
LBPs will be subjected to the normal IND requirements as would any other drug substance. Initial 262 
studies in humans will be concerned with safety, and so are likely to involve healthy volunteers to look 263 
for adverse events (see below).   264 
 265 
Production challenges and scale-up 266 
Many of the commercially successful probiotics that currently dominate the marketplace were 267 
selected in large part based on their technological robustness, by which is meant that they withstand 268 
the process of growth, enrichment, freeze-drying or product incorporation, and retain viability during 269 
product shelf-life. The Bifidobacterium and Lactobacillus species that form the mainstay of the 270 
commercial supply are anaerobic or microaerophilic organisms, but are much less sensitive to 271 
atmospheric oxygen than the strict anaerobes such as Faecalibacterium prausnitzii, Akkermansia 272 
muciniphila and others that are currently being explored as NGPs. Bacterial fermentation is, by 273 
definition, an anaerobic process, but nevertheless current production lines were not developed to 274 
allow harvesting viable bacterial cells with the complete exclusion of oxygen throughout. Even for the 275 
initial product development stage of supporting trials, fermentation of pilot cultures up to 100 litres 276 
is required to prepare inocula for large-scale fermentation in thousand-litre volumes. As a further 277 
12 
 
challenge, the whole process must be performed under GMP conditions that are regulated and 278 
inspected at national level in EU member states. Following fermentation, the microbial cell biomass 279 
requires (typically) to be free-dried, again under strictly anaerobic conditions, followed by microbial 280 
quality control steps (microbial purity, viable cell counts). If being encapsulated, the freeze-dried 281 
material must be milled into an homogenous powder that is tested for galenic properties (powder 282 
characterization, disintegration, dissolution properties). Finally, the powder must be encapsulated in 283 
the absence of oxygen but also with very low water content, with or without excipients or other 284 
agents, typically based on pilot data from intestinal transit studies used to determine how to optimize 285 
viability. This chain of technological stages presents a significant challenge to the large number of 286 
start-up companies aiming to develop novel therapeutics based on anaerobic gut commensals 287 
(reviewed in ref.51) 288 
 289 
Conclusions and Action Required  290 
The term probiotic is not a taxonomic one, but refers to functionality.  Nothing in the definition of 291 
the term limits the species, genus or even Kingdom from which probiotics can be selected, nor does 292 
it dictate whether they must be naive strains or whether they can have been subjected to any form 293 
of genetic manipulation.  Why do we therefore feel the need to use the ter  Ne t Ge eratio  294 
Pro ioti s ?  We believe that it is highly likely that in the near future the enormous amount of 295 
research on the beneficial impact of the microbiome on human health will lead to the discovery and 296 
development of novel microorganisms derived from our microbial symbionts.  In many cases these 297 
a  elo g to u usual a d for erl  u hara terised  i roorga is s ith u usual properties, or 298 
perhaps may even be microorganisms formerly thought of as pathogens or pathobionts.  These 299 
developments will present significant challenges for scientific research, for industrial exploitation 300 
and for regulatory agencies.  For the moment the term NGP can serve as a useful descriptor for 301 
these o -traditio al  i ro es.  Other human commensals developed and approved through a 302 
pharmaceutical route for curing disease or alleviating symptoms will likely retain the LBP moniker. 303 
The success of faecal microbiota transplantation (FMT) for curing diarrhoea associated with 304 
recurrent Clostridium difficile infection 52 has provided a conceptual framework for isolating 305 
organisms or consortia that might improve diseases associated with gut microbiota alteration 53. 306 
These could include GMMs, bacterial spores, or bacteriophages, that would also be more readily 307 
developed as LBPs. 308 
 A suggested development pathway for these products is summarized graphically in Fig. 3. 309 
The most challenging initial task is to identify a candidate LBP. Hypothesis-based approaches to this 310 
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include identifying organisms whose relative abundance levels are depleted in subjects with a 311 
condition associated with an altered microbiome; organisms that are associated with successful FMT 312 
treatment of a particular condition; organisms already known to modulate the microbiome 313 
composition or function; organisms known to influence a particular host pathway or phenotype 314 
relevant to a particular disease. Alternatively, one may screen a bank of strains for a desired in vitro 315 
or in vivo activity. 316 
The next phase is to characterize the LBP, initially by genome sequencing to screen for transmissible 317 
antibiotic resistance genes, and presumptive virulence factors such as toxins. Unless already 318 
performed during candidate LBP screening, trials in enzyme assays, cell models, animal models or ex 319 
vivo models are required to confirm phenotype related to the desired LBP effect. Depending on 320 
strain identity and any safety information for that species or closely related species, safety and 321 
toxicity in animal models may require additional focus. 322 
The production phase should have already been scoped out so that pilot scale, defined medium, 323 
conditions have been established for rapid GMP scale-up. Establishment of an effective formulation 324 
for delivery will include confirmation of LBP survival and bioavailability upon ingestion. GMP product 325 
approval will be required so that production of batches for human trials may commence. 326 
Finally, a typical series of pharmaceutical clinical trials will be implemented. Phase 1 will, for many 327 
LBPs, be a First in Human trial and will establish safety, and examine dosage ranges. Phase 2 will 328 
revolve around the primary endpoint expected for the LBP, in small group sizes. Phase 3 will examine 329 
efficacy, side effects, and relative benefits in larger group. 330 
Accompanying all of these milestones will be achieving deliverables relevant to seeking regulatory 331 
approval by CBER, EDQM or relevant competent authority. These agencies should (continue to) 332 
engage with relevant stakeholders, especially as legislation is being developed, so that all parties 333 
have a clear understanding of precisely what documentation is required for approval of LBPs for 334 
commercial sale. 335 
 336 
Figure Legends 337 
 338 




Figure 2. Schematic diagram summarizing some differences in the history and route to market of 341 
probiotics, next-generation probiotics, and Live Biotherapeutic Products. 342 
 343 
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